Viking (VKTX) Q3 2026 Earnings Call Transcript
Viking reported a third-quarter 2026 net loss of $183.2 million, or $1.55 per share. [[fact-qkrthzhrn]] Third-quarter research and development expenses were $166.8 million, compared with $90 million in the year-earlier period. [[fact-67qnxpdsi]] At September 30, 2026, Viking held $960 million in cash, cash equivalents and short-term investments. [[fact-2vzz4goii]] The company closed concurrent public offerings of common stock and convertible notes, raising approximately $575 million in gross proceeds. [[fact-c3av6ho2y]] In the Phase II VENTURE study, weekly dosing produced mean weight reductions of up to 14.7% from baseline after 13 weeks. [[fact-3ab9t4f7g]] Viking said both VANQUISH studies were fully enrolled. [[fact-a6ahjsz09]]